Abstract 1530P
Background
In the randomized, double-blind, global SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) trials, first-line zolbetuximab + chemo (mFOLFOX6 [SPOTLIGHT]; CAPOX [GLOW]) showed improved PFS (SPOTLIGHT, HR 0.75 [95% CI 0.60, 0.94], P = 0.0066; GLOW, HR 0.69 [95% CI 0.54, 0.87], P = 0.0007) and OS (SPOTLIGHT, HR 0.75 [95% CI 0.60, 0.94], P = 0.0053; GLOW, HR 0.77 [95% CI 0.62, 0.97], P = 0.0118) compared with placebo + chemo in patients with CLDN18.2+, HER2−, LA unresectable or mG/GEJ adenocarcinoma at data cutoff. We present key patient-reported outcome (PRO) findings from these trials.
Methods
Patients completed the EORTC QLQ-C30 and QLQ-OG25 at screening, every 3 weeks on treatment, at discontinuation, and 30 and 90 days thereafter. Changes in scores from baseline, time to confirmed deterioration (TTCD), and time to definitive deterioration (TTDD) in PROs based on literature thresholds were evaluated. Least square mean (LSM) changes from baseline were summarized descriptively. TTCD and TTDD were assessed by Kaplan-Meier estimates and Cox hazard models.
Results
Table describes the LSM changes from baseline for SPOTLIGHT (N = 565) and GLOW (N = 507). No clinically meaningful deteriorations in global health status and quality of life (GHS/QoL), physical functioning (PF), abdominal pain and discomfort, or nausea/vomiting (N/V) were observed. Overall TTCD and TTDD results were similar between arms in both studies.
Table: 1530P
Zolbetuximab + chemo LSM (standard error [SE]) | Placebo + chemo LSM (SE) | Zolbetuximab vs placebo arms LSM (95% CI) | P value | |
SPOTLIGHT Cycle 9 Day 1 | (N = 283) | (N = 282) | ||
GHS/QoL | 1.65 (1.60) | 4.20 (1.77) | -2.54 (-7.02, 1.93) | 0.263 |
PF | -5.68 (1.77) | 0.34 (1.88) | -6.02 (-10.85, -1.19) | 0.015 |
Pain | -6.85 (1.86) | -9.12 (2.08) | 2.27 (-2.97, 7.51) | 0.394 |
N/V | -3.38 (1.64) | -2.31 (1.80) | -1.07 (-5.61, 3.47) | 0.642 |
GLOW Cycle 17 Day1 | (N = 254) | (N = 253) | ||
GHS/QoL | -0.04 (2.43) | -5.55 (2.89) | 5.51 (-1.82, 12.84) | 0.139 |
PF | -2.05 (1.88) | -2.93 (2.19) | 0.88 (-4.67, 6.43) | 0.753 |
Pain | -5.39 (2.32) | -7.27 (2.88) | 1.88 (-5.30, 9.07) | 0.604 |
N/V | -0.95 (1.89) | 2.85 (2.31) | -3.79 (-9.57, 1.98) | 0.192 |
Conclusions
There were not overall clinical HRQoL differences between patients in the zolbetuximab and placebo arms. Zolbetuximab + chemo improved clinical outcomes without negatively affecting HRQoL in key PROs in both SPOTLIGHT and GLOW.
Clinical trial identification
NCT03653507.
Editorial acknowledgement
Medical writing support, conducted in accordance with Good Publication Practice (GPP 2022) and the International Committee of Medical Journal Editors (ICMJE) guidelines, was provided by Ann Ferguson, PhD, of Oxford PharmaGenesis Inc., and was funded by Astellas Pharma Inc.
Legal entity responsible for the study
Astellas Pharma Inc.
Funding
Astellas Pharma Inc.
Disclosure
F. Lordick: Financial Interests, Personal, Advisory Board: Amgen, Astellas, BMS, Bayer, BeiGene, Biontech, Eli Lilly, Elsevier, MSD, Novartis, Roche, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Eli Lilly, Imedex, Incyte, MSD, MedUpdate, Medscape, Merck, Roche, Servier, StreamedUp!, Daiichi Sankyo, Novartis, Art Tempi; Financial Interests, Personal, Writing Engagement: Deutscher Ärzteverlag, Iomedico, Springer-Nature; Financial Interests, Institutional, Research Grant: BMS, Gilead. E. Van Cutsem: Financial Interests, Personal, Advisory Board: AbbVie, ALX, Amgen, Array, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seattle Genetics, Servier, Takeda, Terumo, Taiho, Zymeworks; Financial Interests, Institutional, Research Grant: Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier. K. Shitara: Financial Interests, Personal, Advisory Board: Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, MSD, Taiho, Novartis, AbbVie, GSK, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Guardant Health Japan Corp, Astellas Pharma Inc.; Financial Interests, Personal, Invited Speaker: Janssen Pharmaceutical K.K.; Financial Interests, Institutional, Research Grant: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho, Chugai Pharmaceutical, MSD, Eisai, Amgen. R. Xu: Financial Interests, Personal, Invited Speaker: BMS, MSD; Financial Interests, Personal, Advisory Board: Henrui, BeiGene, Astellas, Merck, Junshi. J.A. Ajani: Financial Interests, Personal, Research Funding: Astellas Pharma Inc.; Financial Interests, Research Funding: Turning Point Therapeutics, Inc., Bristol Myers Squibb, Merck, Taiho Pharmaceutical, Delta-Fly Pharma, Inc., Roche, ProLynx Inc, Zymeworks; Financial Interests, Research Grant: Daiichi Sankyo, Leap Therapeutics, Inc., Gilead Sciences, Inc., Lanova Pharma; Financial Interests, Speaker, Consultant, Advisor: Bristol Myers Squibb, Merck, Astellas Pharma Inc., Amgen, Taiho Pharmaceutical, Zymeworks, BeiGene, AstraZeneca, Daiichi Sankyo, Bayer, GRAIL, Novartis, Geneos, Servier Laboratories, Gilead Sciences, Inc.; Financial Interests, Other, receiving support for travel and/or meeting attendance: Daiichi Sankyo, Bristol Myers Squibb, Merck, BeiGene. M.A. Shah: Financial Interests, Personal, Research Funding: Astellas Pharma Inc., Merck, Bristol Myers Squibb, Oncolys BioPharma; Financial Interests, Personal, Leadership Role: ASCO Leadership Council. M. Oh; A. Ganguli; P. Bhattacharya; M. Matsangou; J.W. Park: Financial Interests, Personal, Full or part-time Employment: Astellas Pharma Global Development, Inc. S. Rhoten: Financial Interests, Personal, Full or part-time Employment: IQVIA. Y. Kang: Financial Interests, Personal, Advisory Board: ALX Oncology, Zymeworks, Amgen, Novartis, MacroGenics, Daehwa, Blueprint, Surface Oncology, BMS, Merck, Roche, LISCure.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21